Bosentan Therapy in Patients With Eisenmenger Syndrome
Top Cited Papers
- 4 July 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 114 (1), 48-54
- https://doi.org/10.1161/circulationaha.106.630715
Abstract
Background— Eisenmenger syndrome is characterized by the development of pulmonary arterial hypertension with consequent intracardiac right-to-left shunt and hypoxemia in patients with preexisting congenital heart disease. Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism. Theoretically, interventions that have some effect on the systemic vascular bed could worsen the shunt and increase hypoxemia. Methods and Results— The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) was a 16-week, multicenter, randomized, double-blind, placebo-controlled study evaluating the effect of bosentan, a dual endothelin receptor antagonist, on systemic pulse oximetry (primary safety end point) and pulmonary vascular resistance (primary efficacy end point) in patients with World Health Organization functional class III Eisenmenger syndrome. Hemodynamics were assessed by right- and left-heart catheterization. Secondary...This publication has 22 references indexed in Scilit:
- Exercise Intolerance in Adult Congenital Heart DiseaseCirculation, 2005
- Pathologic assessment of vasculopathies in pulmonary hypertensionJournal of the American College of Cardiology, 2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJournal of the American College of Cardiology, 2004
- The endothelin system in pulmonary arterial hypertensionCardiovascular Research, 2004
- Management of Grown Up Congenital Heart DiseaseEuropean Heart Journal, 2003
- Eisenmenger's syndrome: Current managementProgress in Cardiovascular Diseases, 2002
- Poor prognosis and related factors in adults with Eisenmenger syndrome.American Heart Journal, 2002
- Eisenmenger syndrome. Factors relating to deterioration and deathEuropean Heart Journal, 1998
- The Eisenmenger Syndrome in AdultsAnnals of Internal Medicine, 1998
- Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndromeThe American Journal of Cardiology, 1993